Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Aurobindo Pharma hopes first biosimilar to receive approval in the US

      Aurobindo Pharma hopes first biosimilar to receive approval in the US

      Farhat Nasim5 Dec 2018 1:03 PM IST
      New Delhi: Aurobindo Pharma's top official said that drug major Aurobindo Pharma expects its first biosimilar product to receive approval in the US in...
      Bal Pharma commenses commercial production at Udaipur unit

      Bal Pharma commenses commercial production at Udaipur unit

      Farhat Nasim5 Dec 2018 3:30 AM IST
      Mumbai: Bal Pharma Ltd. Managing director, Sailesh Siroya recently intimidated the National Stock Exchange that the company after obtaining all the...
      Medical Negligence by Pharma: Report on faulty hip implants ready, Centre informs Supreme Court

      Medical Negligence by Pharma: Report on faulty hip implants ready, Centre informs Supreme Court

      Farhat Nasim4 Dec 2018 11:01 AM IST
      A bench comprising Chief Justice Ranajn Gogoi and Justices S K Kaul and K M Joseph has now asked the Centre to file its response within a week.New...
      Punjab Govt suspends licence of 1000 chemists for violation of guidelines

      Punjab Govt suspends licence of 1000 chemists for violation of guidelines

      Farhat Nasim4 Dec 2018 9:55 AM IST
      A shocking recovery of habit-forming drugs worth Rs 5 crore from 291 units was made by the health department. It also seized oxytocin injections meant...
      Sun Pharma gets USFDA nod for Ganirelix Acetate injection

      Sun Pharma gets USFDA nod for Ganirelix Acetate injection

      Farhat Nasim3 Dec 2018 9:35 AM IST
      NEW DELHI: Through a recent press release the drug major Sun Pharma said it has received final approval from USFDA for its abbreviated new drug...
      USFDA approval to Zydus to market Teriflunomide tablets for MS relapse

      USFDA approval to Zydus to market Teriflunomide tablets for MS relapse

      Farhat Nasim3 Dec 2018 9:15 AM IST
      Zydus group now has 237 approvals from the USFDA and has so far filed over 340 abbreviated new drug applications.New Delhi: Drug firm Zydus Cadila...
      Gilead cell therapy Yescarta proves durable for some lymphoma patients

      Gilead cell therapy Yescarta proves durable for some lymphoma patients

      Farhat Nasim3 Dec 2018 9:00 AM IST
      SAN DIEGO: Nearly 40 per cent of lymphoma patients treated with a single infusion of Gilead Sciences Inc's Yescarta were still responding to the cell...
      Lupin launches Nystatin and Triamcinolone Acetonide in the US market

      Lupin launches Nystatin and Triamcinolone Acetonide in the US market

      Farhat Nasim3 Dec 2018 3:20 AM IST
      The company has launched the product after having received approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in a...
      Regulations on Biotech sector must ease further: Biocon Chief

      Regulations on Biotech sector must ease further: Biocon Chief

      Farhat Nasim2 Dec 2018 12:55 PM IST
      Tax reform has had a minimal impact on the biotechnology sector because it is an export-oriented business, Shaw said. However, the sector is heavily...
      Trouble for Sun Pharma: SEBI likely to reopen insider trading case against Co

      Trouble for Sun Pharma: SEBI likely to reopen insider trading case against Co

      Farhat Nasim1 Dec 2018 9:59 AM IST
      New Delhi: Markets regulator Sebi is likely to reopen an insider trading case against Sun Pharmaceutical Industries as well as probe alleged lapses by...
      Neuland Laboratories announces successful plant inspection by USFDA, no observation

      Neuland Laboratories announces successful plant inspection by USFDA, no observation

      Farhat Nasim1 Dec 2018 9:55 AM IST
      New Delhi: Neuland Laboratories witnessed a surge in its share on Thursday after USFDA issued no observation to its manufacturing facility located at...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok